Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 714 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Prostate Cancer Genomics in Racial Minority Groups February 18, 2021 Addressing Cancer Pain with Complementary Methods (Part 2) April 10, 2023 Reunión anual de la ASCO de 2022: Gasto en servicios sociales... May 26, 2022 Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery November 30, 2018 Load more HOT NEWS Unravelling the mystery of Barrett’s oesophagus Why I Work to Bridge the Gap Between People With Cancer... Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade... FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma
